Development and Validation of Quantitative Real-Time PCR for the Detection of Residual CHO Host Cell DNA and Optimization of Sample Pretreatment Method in Biopharmaceutical Products
Open Access
- 1 September 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Biological Procedures Online
- Vol. 21 (1), 1-7
- https://doi.org/10.1186/s12575-019-0105-1
Abstract
The presence of residual DNA carried by biological products in the body may lead to an increased oncogenicity, infectivity, and immunomodulatory risk. Therefore, current agencies including WHO, EU, and the FDA limited the accepted amounts of residual DNA (less than 10 ng or 100 pg/dose). Among the methods of detecting residual DNA, qPCR is considered to be the most practical for residual DNA quantitation due to its sensitivity, accuracy, precision, and time-saving. In this study, the detection capacity of this method was determined by comparing the detected concentration of the commercial kit and the self-designed primer/probe set after the same treatment of the extraction method. Then, a universal sample pretreatment method based on a co-precipitant was optimized. The validation results demonstrated that the method has appropriate specificity, sensitivity, accuracy, and precision according to ICH guidelines. The limit of detection and quantitation reached 3 fg/ul and 0.3 pg/reaction respectively, which satisfies the requirement of limit of residual DNA detection in biologics. Spike recovery (82.3–105.7%) showed that the proposed qPCR assay was accurate and has good extraction efficiency. Moreover, the precision of the method based on intra- and inter-assay was 0.065–0.452% and 0.471–1.312%, respectively. These results all indicated that the method for determination of residual DNA in biological products expressed from CHO cells is sensitive, accurate and robust.Keywords
This publication has 16 references indexed in Scilit:
- Universal real-time PCR assay for quantitation and size evaluation of residual cell DNA in human viral vaccinesBiologicals, 2016
- A Mouse Strain Defective in Both T Cells and NK Cells Has Enhanced Sensitivity to Tumor Induction by Plasmid DNA Expressing Both Activated H-Ras and c-MycPLOS ONE, 2014
- PER.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccineVaccine, 2013
- Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccinesVaccine, 2012
- From brain passage to cell adaptation: the road of human rabies vaccine developmentExpert Review of Vaccines, 2011
- Quantitative determination of the infectivity of the proviral DNA of a retrovirus in vitro: Evaluation of methods for DNA inactivationBiologicals, 2009
- Issues associated with residual cell-substrate DNA in viral vaccinesBiologicals, 2009
- Suitability of PER.C6® cells to generate epidemic and pandemic influenza vaccine strains by reverse geneticsVaccine, 2009
- An overview of animal cell substrates for biological productsBiologicals, 2008
- Oncogenicity of DNA in vivo: Tumor induction with expression plasmids for activated H-ras and c-mycBiologicals, 2008